Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Afraxis
AddedFeb 15, 2024
UpdatedJun 18, 2026
Afraxis

Afraxis

Public

Afraxis Inc., a US-based company, develops drugs for central nervous system diseases including schizophrenia and alzheimer's.

HQ
San Diego, CA, US
Founded
2007
Overview
Compare
Fundraising
Employees

Afraxis Inc., based in La Jolla, focuses on developing pharmaceutical products targeting central nervous system diseases such as schizophrenia, Alzheimer's disease, fragile X syndrome, and autism spectrum disorders. The company aims to advance treatment options and improve patient outcomes in these critical areas.

Afraxis has made significant strides in CNS drug development, contributing to innovative therapies for complex neurological conditions. Their research and development efforts have positioned them as a key player in the pharmaceutical industry, impacting both clinical practices and patient care.

Afraxis - Similar Companies

Aptinyx logo

Aptinyx

aptinyx.com

Neurana Pharmaceuticals logo

Neurana Pharmaceuticals

neuranapharma.com

Neurolixis logo

Neurolixis

neurolixis.com

Axsome Therapeutics logo

Axsome Therapeutics

axsome.com

Confluence Pharmaceuticals logo

Confluence Pharmaceuticals

Axial Therapeutics logo

Axial Therapeutics

Axonis Therapeutics logo

Axonis Therapeutics

Mithridion logo

Mithridion

Axikin Pharmaceuticals logo

Axikin Pharmaceuticals

NeuroGenetic Pharmaceuticals logo

NeuroGenetic Pharmaceuticals

Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

acadia-pharm.com

Adrx logo

Adrx

adrxpharma.com

Icvrx logo

Icvrx

Psy Therapeutics logo

Psy Therapeutics

psythx.com

Aztherapies logo

Aztherapies

Afraxis - Quick Facts

Who are Afraxis' competitors?

Companies similar to Afraxis include Aptinyx, Neurana Pharmaceuticals, Neurolixis and Axsome Therapeutics.

When was Afraxis founded?

Afraxis was founded in 2007.

Where is Afraxis' headquarters located?

Afraxis' headquarters is located in San Diego, CA, US.

When was Afraxis' last funding round?

Afraxis' most recent funding round was for $300k (USD) in December 2011.

How much has Afraxis raised to-date?

As of Dec 21, 2011, Afraxis has raised a total of $3M (USD).

How many employees does Afraxis have?

Afraxis has 6 employees as of Feb 5, 2024.

Afraxis - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
ISIC
  • 7210Research and experimental development on natural sciences and engineering
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified